FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Clinical trials for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) explained in plain language.
Never miss a new study
Get alerted when new FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) trials appear
Sign up with your email to follow new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine targets rare liver cancer's genetic flaw
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized peptide vaccine for people with fibrolamellar liver cancer or other tumors that have a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to teach the body's immune cells to recognize and attack cancer cells carryin…
Matched conditions: FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Phase: PHASE1 • Sponsor: University Hospital Tuebingen • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 06:03 UTC
-
New vaccine combo targets rare liver cancer in early trial
Disease control Recruiting nowThis early-phase study tests a vaccine designed to target a specific protein found in fibrolamellar carcinoma, a rare liver cancer. The vaccine is given together with two immunotherapy drugs (nivolumab and ipilimumab) to see if it is safe and can boost the body's immune response …
Matched conditions: FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 26, 2026 06:01 UTC